Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bilateral Cancer Clear all
Withdrawn Not applicable Interventional

Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma

NCT00980551
View directory record Official record
Conditions
Retinoblastoma
Interventions
subtenon Carboplatin, Topotecan Hydrochloride, Vincristine, Filgrastim
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 17, 2026, 10:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Recovery of Visual Acuity in People With Vestibular Deficits

NCT00411216
View directory record Official record
Conditions
Vestibular Neuronitis, Vestibular Neuronitis, Bilateral, Vestibular Schwannoma
Interventions
Control exercises, gaze stabilization exercises
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2015 · Synced Oct 17, 2026, 10:26 PM EDT
Completed Phase 2 Interventional

Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)

NCT01751438
View directory record Official record
Conditions
Prostate Cancer
Interventions
Best Systemic Therapy (BST), Best Systemic Therapy (BST) + Surgery or Radiation Therapy, Questionnaires, Phone Call/Email
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
3
States / cities
San Francisco, California • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 17, 2026, 10:26 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

NCT01272037
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
Interventions
Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Systemic Chemotherapy, Tamoxifen Citrate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
5,018 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1435
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 10:26 PM EDT
Terminated Phase 2 Interventional Results available

Hysteroscopic Lymphatic Mapping for Endometrial Cancer

NCT00671606
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Intraoperative Lymphatic Mapping
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 17, 2026, 10:26 PM EDT
Terminated No phase listed Observational

Mesothelioma Early Detection by VOCs

NCT04106973
View directory record Official record
Conditions
Pleural Mesothelioma, Asbestos Exposure, Pleural Plaque
Interventions
Not listed
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 10:26 PM EDT
Terminated Phase 2 Interventional

Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy

NCT00505492
View directory record Official record
Conditions
Uterine Neoplasms
Interventions
Carboplatin, Cisplatin, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Oct 17, 2026, 10:26 PM EDT
Completed Phase 4 Interventional Results available

A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy

NCT00106392
View directory record Official record
Conditions
Erectile Dysfunction, Prostate Cancer
Interventions
Tacrolimus, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Up to 65 Years · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
6
States / cities
Ann Arbor, Michigan • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Oct 17, 2026, 10:26 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25

NCT06227676
View directory record Official record
Conditions
Dysmenorrhea Primary, Dysmenorrhea, Menstrual Discomfort, Menstrual Problem, Menstrual Cycle Abnormal, Menstrual Pain, Period Pain, Period Problem, PMS, Premenstrual Syndrome, PCOS, PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, PCOS (Polycystic Ovary Syndrome) of Left Ovary, PCOS (Polycystic Ovary Syndrome) of Right Ovary, Polycystic Ovary Syndrome, Premenstrual Dysphoric Disorder, Cramps, Ovarian Cysts
Interventions
Cramp Bites by Aunt Flo's Kitchen
Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 17, 2026, 10:26 PM EDT
Terminated Phase 4 Interventional Results available

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

NCT00924950
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis Vulgaris
Interventions
Taclonex Ointment and Hydrogel Patch, Taclonex Ointment
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 17, 2026, 10:26 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome

NCT06050265
View directory record Official record
Conditions
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Dysglycemia, Insulin Resistance
Interventions
DEXCOM Continuous Glucose Monitor (CGM)
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 17, 2026, 10:26 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage

NCT05554211
View directory record Official record
Conditions
Breast Cancer, BRCA Mutation
Interventions
Tranexamic acid, Normal saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 17, 2026, 10:26 PM EDT
Recruiting Not applicable Interventional

Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves

NCT02310399
View directory record Official record
Conditions
Hearing Loss, Bilateral (Causes Other Than Tumors)
Interventions
Nucleus ABI541 Auditory Brainstem Implant
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Months to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 17, 2026, 10:26 PM EDT
Recruiting Phase 3 Interventional

Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

NCT05819853
View directory record Official record
Conditions
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
Interventions
Semaglutide Injectable Product (Wegovy and/or Ozempic)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 35 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 17, 2026, 10:26 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft

NCT04263025
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cryopreserved Umbilical Cord Allograft, Robot-Assisted Radical Prostatectomy
Biological · Procedure
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
30 Years to 70 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 17, 2026, 10:26 PM EDT
Recruiting Phase 1 Interventional

TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma

NCT07862647
View directory record Official record
Conditions
Glioblastom WHO Grade 4, GBM, bGBM, Butterfly GBM, Bihemispheric GBM, Glioblastoma
Interventions
5-ALA, Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound
Drug · Device
Lead sponsor
Alpheus Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 10:26 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07248144, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
102
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 17, 2026, 10:26 PM EDT
Active, not recruiting Phase 2 Interventional

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

NCT00877500
View directory record Official record
Conditions
Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma
Interventions
Best Practice, Ixabepilone
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
3
States / cities
Oak Lawn, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 17, 2026, 10:26 PM EDT
Terminated Not applicable Interventional Results available

Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects

NCT01736267
View directory record Official record
Conditions
Bilateral Hearing Loss for Causes Other Than Tumors
Interventions
Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 17, 2026, 10:26 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

NCT04052555
View directory record Official record
Conditions
Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Berzosertib, Biospecimen Collection, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 17, 2026, 10:26 PM EDT
Completed Not applicable Interventional

Genetic Counseling for Breast Cancer Survivors (GC for BC)

NCT02451735
View directory record Official record
Conditions
Breast Cancer
Interventions
Video and Booklet, Factsheet
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 17, 2026, 10:26 PM EDT
Active, not recruiting Phase 3 Interventional

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
216
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 10:26 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Rituximab in Neuromyelitis Optica

NCT00501748
View directory record Official record
Conditions
Neuromyelitis Optica
Interventions
Rituximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 86 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
San Francisco, California • Columbia University Medical Center 710 West 168th Street,, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 17, 2026, 10:26 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

New Approach to Objectively Measure Social Engagement in Older Adults With Hearing Loss

NCT06781749
View directory record Official record
Conditions
Hearing Loss, Bilateral (Causes Other Than Tumors)
Interventions
Hearing aid use
Device
Lead sponsor
University of Southern California
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 17, 2026, 10:26 PM EDT